Journal of Peking University (Health Sciences) ›› 2022, Vol. 54 ›› Issue (6): 1074-1078. doi: 10.19723/j.issn.1671-167X.2022.06.003

Previous Articles     Next Articles

Role of the CCL28-CCR10 pathway in monocyte migration in rheumatoid arthritis

Fang CHENG1,*(),Shao-ying YANG2,Xing-xing FANG3,Xuan WANG3,Fu-tao ZHAO1,*()   

  1. 1. Department of Rheumatology and Immunology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201999, China
    2. Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China
    3. Department of Rheumatology and Immunology, Tongji Hospital, Tongji University, Shanghai 200065, China
  • Received:2022-07-13 Online:2022-12-18 Published:2022-12-19
  • Contact: Fang CHENG,Fu-tao ZHAO E-mail:chengfangsmmu@126.com;ftzhao@moisten.org
  • Supported by:
    the National Natural Science Foundation of China(81302562)

RICH HTML

  

Abstract:

Objective: To examine the expression of chemokine receptor CCR10 on monocytes/macrophages in the joints of patients with rheumatoid arthritis (RA), and to investigate the role of chemokine CCL28 and its receptor CCR10 in the migration of RA monocytes and its mechanism. Methods: The expression of CCR10 in synovial tissues from 8 RA patients, 4 osteoarthritis (OA) patients, and 4 normal controls was analyzed by immunohistochemistry, and cell staining was scored on a 0-5 scales. Flow cytometry was used to measure the percentage of CCR10 positive cells in CD14+ monocytes from peripheral blood of 26 RA patients and 20 healthy controls, as well as from synovial fluid of 15 RA patients. The chemotactic migration of monocytes from RA patients and healthy controls in response to CCL28 was evaluated using an in vitro Transwell system. Western blotting was conducted to assess phosphorylation of the extracellular signal-regulated kinase (ERK) and protein kinase B (Akt) pathways in RA monocytes upon CCL28 treatment. Results: CCR10 was predominantly expressed in RA synovial lining cells and sublining macrophages, endothelial cells, and lymphocytes. CCR10 expression was significantly increased on lining cells and sublining macrophages in RA synovial tissue compared with OA and normal synovial tissue (both P < 0.01). The patients with RA had markedly elevated expression of CCR10 on peripheral blood CD14+ monocytes compared with the healthy controls [(15.6±3.0)% vs. (7.7±3.8)%, P < 0.01]. CCR10 expression on synovial fluid monocytes from the RA patients was (32.0±15.0)%, which was significantly higher than that on RA peripheral blood monocytes (P < 0.01). In vitro, CCL28 caused significant migration of CD14+ monocytes from peripheral blood of the RA patients and the healthy controls at concentrations ranging from 10-100 μg/L (all P < 0.01). The presence of neutralizing antibody to CCR10 greatly suppressed CCL28-driven chemotaxis of RA monocytes (P < 0.01). Stimulation of RA monocytes with CCL28 induced a remarkable increase in phosphorylation of ERK and Akt (both P < 0.05). ERK inhibitor (U0126) and phosphatidylinositol 3-kinase (PI3K) inhibitor (LY294002) strongly reduced the migration of RA monocytes in response to CCL28 (both P < 0.01). Conclusion: RA patients had increased CCR10 expression on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages. CCL28 ligation to CCR10 promoted RA monocyte migration through activation of the ERK and PI3K/Akt signaling pathways. The CCL28-CCR10 pathway could participate in monocyte recruitment into RA joints, thereby contributing to synovial inflammation and bone destruction.

Key words: Rheumatoid arthritis, Monocytes, Chemokine CCL28, Chemokine receptor CCR10

CLC Number: 

  • R593.22

Figure 1

The expression of CCR10 in synovial tissues (immunohistochemical staining) A, rheumatoid arthritis; B, osteoarthritis; C, normal controls."

Figure 2

CCR10 expression on monocytes in peripheral blood and synovial fluid HC, healthy controls; RA, rheumatoid arthritis; PB, peripheral blood; SF, synovial fluid; PE, phycoerythrin."

Figure 3

The chemotactic migration of monocytes in response to CCL28 * P < 0.01, vs. PBS. PBS, phosphate buffered saline."

Figure 4

Phosphorylation of the ERK and Akt signaling pathways in monocytes after CCL28 stimulation * P < 0.05, ** P < 0.01, vs. CCL28 at 0 min. ERK, extracellular signal-regulated kinase; Akt, protein kinase B; GAPDH, glyceraldehyde-3-phosphatedehydrogenase; p-ERK and p-Akt, phosphorylation products of ERK and Akt, respectively."

Figure 5

Effects of inhibiting CCR10, ERK and PI3K/Akt on CCL28-driven monocyte chemotaxis A, phosphate buffered saline; B, control IgG; C, anti-CCR10 antibody (1 mg/L); D, dimethyl sulfoxide; E, U0126 (ERK inhibitor, 10 μmol/L); F, LY294002 (PI3K inhibitor, 10 μmol/L). Mononuclear cells were pretreated with A-F for 45 min and then incubated for 1 h in a Transwell chamber without or with CCL28 (10 μg/L). * P < 0.01, vs. control IgG; # P < 0.01, vs. dimethyl sulfoxide."

1 Sparks JA . Rheumatoid arthritis[J]. Ann Intern Med, 2019, 170 (1): ITC1- ITC16.
doi: 10.7326/AITC201901010
2 Jang S , Kwon EJ , Lee JJ . Rheumatoid arthritis: Pathogenic roles of diverse immune cells[J]. Int J Mol Sci, 2022, 23 (2): 905.
doi: 10.3390/ijms23020905
3 Szekanecz Z , Koch AE . Successes and failures of chemokine-pathway targeting in rheumatoid arthritis[J]. Nat Rev Rheumatol, 2016, 12 (1): 5- 13.
doi: 10.1038/nrrheum.2015.157
4 Pan J , Kunkel EJ , Gosslar U , et al. A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues[J]. J Immunol, 2000, 165 (6): 2943- 2949.
doi: 10.4049/jimmunol.165.6.2943
5 Wang W , Soto H , Oldham ER , et al. Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2)[J]. J Biol Chem, 2000, 275 (29): 22313- 22323.
doi: 10.1074/jbc.M001461200
6 Mohan T , Deng L , Wang BZ . CCL28 chemokine: An anchoring point bridging innate and adaptive immunity[J]. Int Immuno-pharmacol, 2017, 51, 165- 170.
doi: 10.1016/j.intimp.2017.08.012
7 Chen Z , Kim SJ , Essani AB , et al. Characterising the expression and function of CCL28 and its corresponding receptor, CCR10, in RA pathogenesis[J]. Ann Rheum Dis, 2015, 74 (10): 1898- 1906.
doi: 10.1136/annrheumdis-2013-204530
8 Miyazaki Y , Nakayamada S , Kubo S , et al. Th22 cells promote osteoclast differentiation via production of IL-22 in rheumatoid arthritis[J]. Front Immunol, 2018, 9, 2901.
doi: 10.3389/fimmu.2018.02901
9 Aletaha D , Neogi T , Silman AJ , et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Arthritis Rheum, 2010, 62 (9): 2569- 2581.
doi: 10.1002/art.27584
10 Rana AK , Li Y , Dang Q , et al. Monocytes in rheumatoid arthritis: Circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis[J]. Int Immunopharmacol, 2018, 65, 348- 359.
doi: 10.1016/j.intimp.2018.10.016
11 Park J , Zhang X , Lee SK , et al. CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion[J]. J Clin Invest, 2019, 129 (12): 5381- 5399.
doi: 10.1172/JCI125336
12 Facciabene A , Peng X , Hagemann IS , et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells[J]. Nature, 2011, 475 (7355): 226- 230.
doi: 10.1038/nature10169
13 Wu Q , Chen JX , Chen Y , et al. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation[J]. Cell Death Dis, 2018, 9 (2): 232.
doi: 10.1038/s41419-018-0267-9
[1] Hui WEI, Jingfeng ZHANG, Zhongqiang YAO, Jinxia ZHAO. Clinical characteristics and relevant factors of rheumatoid arthritis patients with anemia of chronic disease [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 307-312.
[2] Tao WU, Jianzi LIN, Yafeng ZHU, Jianda MA, Peiwen JIA, Lijuan YANG, jie PAN, Yaowei ZOU, Ying YANG, Ye LU, Lie DAI. Serum inter-alpha-trypsin inhibitor heavy chain H3 is identified as a potential biomarker for myopenia in patients with rheumatoid arthritis using proteomic profiling [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1024-1031.
[3] Yan DING, Lifang WANG, Chaoran LI, Zhemin LU, Lianjie SHI. Rheumatoid arthritis combined with IgG4-related disease successfully treated with rituximab: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1203-1207.
[4] Ju YANG, Jing XU, Juhua DAI, Lianjie SHI. Expression of lumican protein in serum of patients with rheumatoid arthritis and its correlation with disease and immune activities [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 911-918.
[5] Lianghua FENG, Lirong HONG, Yujia CHEN, Xueming CAI. Role and mechanism of ubiquitin-specific protease 35 in ferroptosis of rheumatoid arthritis-fibroblast like synoviocytes [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 919-925.
[6] Peiwen JIA, Ying YANG, Yaowei ZOU, Zhiming OUYANG, Jianzi LIN, Jianda MA, Kuimin YANG, Lie DAI. Clinical characteristics of overlapping syndromes of low muscle mass in patients with rheumatoid arthritis and their impact on physical function [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1009-1016.
[7] Doudou MA, Zhemin LU, Qian GUO, Sha ZHU, Jin GU, Yan DING, Lianjie SHI. Successful treatment of rheumatoid arthritis complicated with myasthenia gravis with low-dose rituximab: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1110-1114.
[8] Rui YAN, Dan KE, Yan ZHANG, Li LI, Huanran SU, Wei CHEN, Mingxia SUN, Xiaomin LIU, Liang LUO. Diagnostic significance of serum chemokine CXCL-10 and Krebs von den lungen-6 level in patients with rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 956-962.
[9] Liang ZHAO, Chenglong SHI, Ke MA, Jing ZHAO, Xiao WANG, Xiaoyan XING, Wanxing MO, Yirui LIAN, Chao GAO, Yuhui LI. Immunological characteristics of patients with anti-synthetase syndrome overlap with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 972-979.
[10] Yijun HAN, Xiaoli CHEN, Changhong LI, Jinxia ZHAO. Application status of methotrexate in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 994-1000.
[11] Dongwu LIU, Jie CHEN, Mingli GAO, Jing YU. Rheumatoid arthritis with Castleman-like histopathology in lymph nodes: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 928-931.
[12] Huina HUANG,Jing ZHAO,Xiangge ZHAO,Ziran BAI,Xia LI,Guan WANG. Regulatory effect of lactate on peripheral blood CD4+ T cell subsets in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 519-525.
[13] Xiaofei TANG,Yonghong LI,Qiuling DING,Zhuo SUN,Yang ZHANG,Yumei WANG,Meiyi TIAN,Jian LIU. Incidence and risk factors of deep vein thrombosis in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 279-283.
[14] Xue ZOU,Xiao-juan BAI,Li-qing ZHANG. Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1013-1021.
[15] Qi WU,Yue-ming CAI,Juan HE,Wen-di HUANG,Qing-wen WANG. Correlation between dyslipidemia and rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 982-992.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!